Table 2. Lipids and HDL-mediated cholesterol efflux capacity at baseline (n=74).
| Parameter | All patients (n=74) | ABCA1 CEC | ABCG1 CEC | SR-BI CEC | |||||
|---|---|---|---|---|---|---|---|---|---|
| ≤ median | > median | ≤ median | > median | ≤ median | > median | ||||
| Lipids | |||||||||
| T-Cho, mg/dL | 174 [135, 209] | 155 [124, 197] | 186 [159, 209] | 159 [128, 193] | 182 [151, 213] | 159 [112, 197] | 182 [151, 209] | ||
| LDL-C, mg/dL | 97 [77, 135] | 97 [62, 131] | 101 [85, 139] | 89 [66, 128] | 101 [85, 135] | 101 [62, 135] | 97 [81, 131] | ||
| HDL-C, mg/dL | 41 [35, 46] | 39 [35, 43] | 43 [35, 50] | 35 [31, 43] | 46* [39, 50] | 35 [31, 39] | 46*** [43, 54] | ||
| TG, mg/dL | 124 [89, 168] | 97 [71, 159] | 151* [115, 177] | 133 [89, 168] | 124 [89, 168] | 142 [71, 204] | 124 [89, 159] | ||
| HDL-mediated cholesterol efflux capacity | |||||||||
| ABCA1 CEC (%) | 22.6 [20.7, 24.5] | 20.7 [19.8, 22.0] | 24.5*** [23.6, 25.7] | 22.0 [20.1, 24.2] | 23.4 [21.2, 24.5] | 22.5 [20.1, 24.4] | 22.9 [21.2, 24.6] | ||
| ABCG1 CEC (%) | 3.4 [3.1, 4.1] | 3.3 [3.0, 4.0] | 3.7* [3.2, 4.2] | 3.1 [2.9, 3.3] | 4.1*** [3.8, 4.3] | 3.3 [3.0, 3.8] | 3.7 [3.2, 4.2] | ||
| SR-BI CEC (%) | 10.4 [9.5, 12.3] | 10.2 [8.8, 11.7] | 10.9 [9.8, 12.6] | 9.9 [9.2, 11.0] | 11.7** [10.2, 13.1] | 9.5 [8.6, 10.1] | 12.3*** [11.3, 13.4] | ||
Patients were stratified into two groups according to the cut-off values calculated as median values from baseline HDL-mediated CEC (ABCA1 CEC: 22.6%; ABCG1 CEC: 3.4%; SR-BI CEC: 10.4%; respectively). Values are median [interquartile range]. *, P<0.05; **, P<0.01; ***, P<0.001. ABCA1 CEC, ATP-binding cassette transporter A1-mediated cholesterol efflux capacity; ABCG1 CEC, ATP-binding cassette transporter G1-mediated cholesterol efflux capacity; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SR-BI CEC, scavenger receptor B type I-mediated cholesterol efflux capacity; T-Cho, total cholesterol; TG, triglyceride.